Cargando…

Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study

BACKGROUND: Renin–angiotensin–aldosterone system (RAAS) blockade with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) is the cornerstone of antihypertensive treatment in patients with chronic kidney disease (CKD) and diabetes mellitus. Mineralocorticoid recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovarik, Johannes J., Kaltenecker, Christopher C., Domenig, Oliver, Antlanger, Marlies, Poglitsch, Marko, Kopecky, Chantal, Säemann, Marcus D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384966/ https://www.ncbi.nlm.nih.gov/pubmed/34351585 http://dx.doi.org/10.1007/s13300-021-01118-7

Ejemplares similares

Molecular remodeling of the renin-angiotensin system after kidney transplantation
por: Antlanger, Marlies, et al.
Publicado: (2017)

Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
por: Antlanger, Marlies, et al.
Publicado: (2022)

Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation
por: Kovarik, Johannes J., et al.
Publicado: (2019)

Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney
por: Domenig, Oliver, et al.
Publicado: (2016)

A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation
por: Werzowa, Johannes M., et al.
Publicado: (2018)

Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System
por: Poglitsch, Marko, et al.
Publicado: (2012)

Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2021)

Fluid overload in hemodialysis patients: a cross-sectional study to determine its association with cardiac biomarkers and nutritional status
por: Antlanger, Marlies, et al.
Publicado: (2013)

Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
por: Schwaiger, Elisabeth, et al.
Publicado: (2019)

Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury
por: Luther, James M., et al.
Publicado: (2012)

Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex
por: Caroccia, Brasilina, et al.
Publicado: (2021)

Dipeptidyl peptidase 3 modulates the renin–angiotensin system in mice
por: Jha, Shalinee, et al.
Publicado: (2020)

Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping
por: Antlanger, Marlies, et al.
Publicado: (2018)

The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
por: Hartl, Lukas, et al.
Publicado: (2023)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
por: Mortensen, Line Aas, et al.
Publicado: (2017)

Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage
por: Fels, Benedikt, et al.
Publicado: (2022)

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
por: Königsbrügge, Oliver, et al.
Publicado: (2017)

GLUCOCORTICOID-INDUCED HYPERTENSION AND CARDIAC INJURY: EFFECTS OF MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ANTAGONISM
por: HATTORI, TAKUYA, et al.
Publicado: (2013)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx
por: Crompton, Michael, et al.
Publicado: (2023)

Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension
por: Burke, Sandra L., et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice
por: Palacios-Ramirez, Roberto, et al.
Publicado: (2022)

Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
por: Fraccarollo, Daniela, et al.
Publicado: (2015)

Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females
por: Clemmer, John S., et al.
Publicado: (2019)

Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV
por: Srinivasa, Suman, et al.
Publicado: (2021)

SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
por: Burrello, Jacopo, et al.
Publicado: (2020)

Aldosterone nongenomically induces angiotensin II receptor dimerization in rat kidney: role of mineralocorticoid receptor and NADPH oxidase
por: Sinphitukkul, Kittisak, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonism Attenuates Multiple Organ Failure after Renal Ischemia and Reperfusion in Mice
por: Park, Eun Jung, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction
por: Schena, Elisa, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension
por: Alves-Lopes, Rhéure, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
por: Eudy, Rena J, et al.
Publicado: (2011)

The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional Stimuli
por: Young, Kymberly D., et al.
Publicado: (2016)

Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve
por: Ibarrola, Jaime, et al.
Publicado: (2020)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Effects of Endogenous Angiotensin II on Abdominal Aortic Aneurysms and Atherosclerosis in Angiotensin II–Infused Mice
por: Kukida, Masayoshi, et al.
Publicado: (2021)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis
por: Odler, Balazs, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p1jqt9oojrdbjaol879om1jsnu